In preclinical mouse models, tabersonine effectively inhibits NLRP3 inflammasome-mediated signaling, downregulates pro-inflammatory cytokine expression, inhibits the activation of microglia, and significantly improves LPS-induced depression-like behaviors (206). Here, NLRP3 is linked to depressive disorder.